Obese children with Moderate to Severe Sleep Apnea would have baseline evaluation of markers of cardiometabolic risk and insulin resistance. Subjects will then use CPAP for 3 months and will return for another blood draw for measurement of the markers for cardiometabolic risk and insulin resistance.
Inclusion Criteria:
1. Body mass index greater than 95th percentile for age and gender
2. Moderate to severe OSA (as defined by an apnea-hypopnea index [AHI] score of ≥5 events per hour).
Only patients who provide informed assent or consent and also have consent from a parent will be included.
Exclusion Criteria:
1. Predominant central sleep apnea
2. Type 1 Diabetes
3. Type 2 Diabetes
4. Requires use of supplemental oxygen
5. Active infection, cancer, or chronic inflammatory disorder
6. Use of systemic steroids
7. Simultaneous use of peroxisome proliferator-activated receptor (PPAR)-alpha (e.g., gemfibrozil, fenofibrate) or PPAR-gamma (e.g., rosiglitazone, pioglitazone)
Last updated: 02/25/2013
NCT ID: NCT01403194
IRB Number:10-004698
Find Mayo Clinic on